A damning report highlights the negative impact of Brexit on British cancer patients, who face increased costs and red tape in accessing life-saving drugs and clinical trials. The report indicates that while patients in Europe benefit from new treatments, UK patients suffer from delays and rising expenses, which have quadrupled for drug imports. Some trials have seen shipping costs soar, creating significant barriers to research and innovations critical for patient care, particularly for children. Experts from major organizations compiled the report, urging government action to address these urgent issues.
British cancer patients are being denied life-saving drugs, with Brexit creating red tape and extra costs that obstruct their access to pioneering treatments.
A comprehensive report reveals that while Europe enjoys advancements in cancer treatment, the UK's post-Brexit complications have put patients at a disadvantage.
Collection
[
|
...
]